Alastair Smith, Chief Executive Officer, commented: “Selection of the Affimer PD-L1 inhibitor candidate for clinical development is an important milestone in our development of the Affimer therapeutic platform. The Group
Affimer reagents and therapeutics are a class of non-antibody binding proteins that have been engineered for a wide range of applications where antibodies and aptamers have limitations. They can be
Avacta Group plc (LON: AVCT), the developer of Affimer® biotherapeutics and research reagents, announced that it is planning to submit an IND/CTA application early in 2020 to test the TMACTM
Over 18,000 leaders in Biotech and Pharma attended the 2018 BIO convention. This year the Avacta team will be exhibiting and will be found on booth 3559. Avacta Group Plc
The word “cancer” itself is enough to evoke terror, with global incidence of the often-fatal disease on the rise: From 14.1 million in 2012, the number of cases had risen
Over 6% of global food production is lost due to pathogens, including plant viruses. Plant viruses in the field are often mismanaged or unmanaged due to difficulties in detection of
In 2017, the first immuno-oncology cell therapies, known as chimeric antigen receptor T cells, or CAR T, were approved by the U.S. Food and Drug Administration. Immuno-oncology cell therapy is
finnCap’s Mark Brewer discusses Avacta Group Plc in this exclusive interview with DirectorsTalk
Last year’s Nobel prize in physiology or medicine went to James P Allison and Tasuku Honjo for their work on cancer immunotherapy. Some doctors think that the emerging use of
Avacta Group plc (LON: AVCT) is the topic of conversation when Mark Brewer Director of Life Sciences at finnCap joins DirectorsTalk. Mark explains the implications of taking its first Affimer into
© 2024 – DirectorsTalk. All rights reserved. Reproduction in whole or in part, in any form or medium without express written permission is prohibited.
